The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

@article{Drucker2006TheIS,
  title={The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes},
  author={Daniel J. Drucker and Michael A. Nauck},
  journal={The Lancet},
  year={2006},
  volume={368},
  pages={1696-1705}
}
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics), and inhibitors of dipeptidyl peptidase-4 (DPP-4) activity (incretin enhancers). Clinical trials with the incretin mimetic exenatide (two injections per day or long-acting release… Expand

Paper Mentions

Interventional Clinical Trial
Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase… Expand
ConditionsIncretinomimetics, Pancreas, Type 2 Diabetes
InterventionDrug
Observational Clinical Trial
This is a cross-sectional observational study aiming to examine and compare the impact of incretin based therapies i.e. dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-like… Expand
ConditionsCardiovascular Diseases, Diabetes Mellitus, Type 2
Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors
TLDR
Clinical trials with the incretin mimetic exenatide and liraglutide show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c, associated with weight loss, and the most common adverse event associated with Glucagon-like peptide-1 receptor agonists is nausea, which lessens over time. Expand
An update in incretin-based therapy: a focus on glucagon-like peptide-1 receptor agonists.
TLDR
For T2DM patients willing to use an injectable agent, exenatide and liraglutide offer another therapeutic option to control hyperglycemia with the potential for weight loss and may be combined with other agents safely. Expand
Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
TLDR
These compounds may play an important role in the treatment of patients with T2DM as their potential effects go beyond glucose-lowering (weight loss, potential improvement of cardiovascular risk factors). Expand
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
TLDR
The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of GLP-1 receptor agonists, which have been shown to reduce A1C, body weight, blood pressure, and lipids. Expand
GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
TLDR
According to current clinical guidelines, GLP-1RA and DPP-4 inhibitors are both indicated for the glycemic management of patients with T2DM across the spectrum of disease and, as expected, improved glycemic control and weight loss are seen following the switch. Expand
Incretin hormone mimetics and analogues in diabetes therapeutics.
  • B. Green, P. Flatt
  • Medicine
  • Best practice & research. Clinical endocrinology & metabolism
  • 2007
TLDR
The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions and represent one of the newest classes of antidiabetic drug. Expand
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
  • B. Gallwitz
  • Medicine
  • Handbook of experimental pharmacology
  • 2011
TLDR
An overview on the mechanism of action and the substances and clinical data available is given and GLP-1 receptor agonists allow weight loss; DPP-4 inhibitors are weight neutral. Expand
Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
TLDR
In conclusion, incretin therapy is safe with very few adverse events and an additional value of the therapy is a very low risk for hypoglycaemia. Expand
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.
TLDR
An overview of current and emerging agents that augment the incretin system with a focus on the role of GLP-1 receptor agonists and DPP-4 inhibitors is provided. Expand
Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4.
TLDR
In both mice and rats, peripheral GLP-1 reduces food intake significantly less than Ex-4, even when protected from DPP-4; these findings suggest distinct potencies of GLp-1 receptor agonists on food intake that cannot be explained by plasma pharmacokinetics. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 145 REFERENCES
Therapeutic strategies based on glucagon-like peptide 1.
Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on the pancreatic beta-cells, and inhibitory effects onExpand
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
TLDR
In mild type-2 diabetes, GLP-1 [7-36 amide], in contrast to GIP, retains much of its insulinotropic activity and lowers glucagon concentrations. Expand
The biology of incretin hormones.
TLDR
Current concepts of incretin action are summarized and the potential therapeutic utility of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes is highlighted. Expand
Glucagon-like peptide 1 and its derivatives in the treatment of diabetes
TLDR
It is hoped that this new class of drugs interacting with the GLP-1 or other incretin receptors, the so-called "incretin mimetics", will broaden the armamentarium of antidiabetic medications in the nearest future. Expand
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.
TLDR
Findings illustrate that peripheral administration of a larger peptide-albumin recombinant protein mimics GLP-1R-dependent activation of central and peripheral pathways regulating energy intake and glucose homeostasis in vivo. Expand
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
TLDR
It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo and reports of circulating hormone levels should be reconsidered. Expand
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
TLDR
Improved metabolic control by DPP-4 inhibition in type 2 diabetes is seen in association with reduced glucagon levels and, despite the lower glycemia, unaltered insulin levels. Expand
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.
TLDR
The suppression of glucagon by GLP-1 does occur at euglycemia, but not at hypoglycemic plasma glucose concentrations, which is in line with other findings demonstrating pituitary actions of GLp-1. Expand
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
TLDR
Findings demonstrate that an albumin-conjugated DAC:GLP-1 mimics the action of native GLP- 1 and represents a new approach for prolonged activation of GLP -1R signaling. Expand
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
TLDR
Exogenous GLP-1 (7-36 amide) is an effective means of normalizing fasting plasma glucose concentrations in poorly-controlled Type 2 diabetic patients. Expand
...
1
2
3
4
5
...